Wed, August 10, 2022

Swayampakula Ramakanth Maintained (BCAB) at Strong Buy with Decreased Target to $20 on, Aug 10th, 2022

Swayampakula Ramakanth of HC Wainwright & Co., Maintained "BioAtla, Inc." (BCAB) at Strong Buy with Decreased Target from $25 to $20 on, Aug 10th, 2022.

Swayampakula, nor any peers, have made any analyst calls on BCAB in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30